Home, daily intelligence digest and feed
Good evening
Based on 650 claims across 27 sources · June 9, 2026
Today's digest
Jun 9, 2026 · 6 highlights · 5 sources
Microsoft determined it could not remain structurally dependent on a third party like OpenAI for superintelligence IP in the long term.
According to Mustafa Suleyman, this led to an October 2023 contract that frees Microsoft to pursue superintelligence development independently while continuing the partnership.
Decoder
Mustafa SuleymanApple confirmed its new "Siri AI" will be available as a standalone application and will be powered by Google's Gemini foundation model.
Ed Ludlow reports the new chatbot-style interface will use Gemini for both on-device and cloud-based processing, marking a significant partnership between the tech giants.
Balance of Power
Joe Matthew and Kailey LeinzPalo Alto Networks discovered vulnerabilities in its codebase in just 6 weeks using the AI tool Mythos, a task estimated to take 5 to 7 years manually.
CEO Nikesh Arora noted the tool's significant acceleration in vulnerability detection, though he also reported a 30% false positive rate during testing.
All-In Podcast
Nikesh AroraThe House Oversight Committee confirmed $300 million in federal child nutrition fund fraud occurred in Minnesota.
Representative James Comer stated that whistleblowers testified under oath that they had warned Governor Tim Walz and Attorney General Keith Ellison, but no action was taken.
Balance of Power
Kailey Leinz and Joe Matthew+2 more highlights from Merryn Talks Money, Bloomberg Businessweek Daily
Latest Episodes
Tracking
+ Track moreSign in to track people, companies, and topics.
Sign inYour projects
Sign in to create and track research projects.
Deep dive prompts
What are the biggest risks if the US loses the AI race to China?
How will AI change venture capital fund returns?
Which companies are best positioned for the energy transition?
What do experts disagree on about AI safety?
How is custom silicon threatening NVIDIA's dominance?
What's the real impact of GLP-1 drugs on healthcare spending?
Your subscriptions
Sign up free to access your personalized dashboard
Get started free